Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abiraterone Acetate

FDA-approved product (tablet, oral), marketed as Abiraterone Acetate, Yonsa, Zytiga.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Abiraterone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abiraterone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abiraterone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

    NCT04175431 · start 2020-09-30

    Registered record
    Registry ID
    NCT04175431
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Positron Emission Tomography; Lymphadenectomy; Radiation Therapy; Abiraterone Acetate; Prednisone; Computed Tomography; Abiraterone; PSMA PET Scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-09-30
    Completion
    2037-07-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionPositron Emission Tomography; Lymphadenectomy; Radiation Therapy; Abiraterone Acetate +4 more
    PhasePhase 2
    Registry statusRecruiting

  • PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    NCT04556617 · start 2020-09-21

    Registered record
    Registry ID
    NCT04556617
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    PLX2853 20 mg; Olaparib; Abiraterone acetate; Prednisone; PLX2853 40 mg; PLX2853 80 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-09-21
    Completion
    2022-05-24
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionPLX2853 20 mg; Olaparib; Abiraterone acetate; Prednisone +2 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

    NCT04495179 · start 2020-08-04

    Registered record
    Registry ID
    NCT04495179
    Conditions
    Progressive Metastatic Castrate-Resistant Prostate Cancer
    Interventions
    AZD4635; Durvalumab; Cabazitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-08-04
    Completion
    2022-08-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Metastatic Castrate-Resistant Prostate Cancer
    InterventionAZD4635; Durvalumab; Cabazitaxel
    PhasePhase 2
    Registry statusCompleted

  • Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

    NCT03777982 · start 2020-04-20

    Registered record
    Registry ID
    NCT03777982
    Conditions
    Prostate Cancer
    Interventions
    Prednisone; Apalutamide; Abiraterone Acetate; LHRH Agonist or Antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-04-20
    Completion
    2024-02-13
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPrednisone; Apalutamide; Abiraterone Acetate; LHRH Agonist or Antagonist
    PhasePhase 3
    Registry statusTerminated

  • A Study Designed to Evaluate the Pharmacokinetic Profile of Abiraterone

    NCT04295161 · start 2019-06-25

    Registered record
    Registry ID
    NCT04295161
    Conditions
    Pharmacokinetics
    Interventions
    Abiraterone Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-25
    Completion
    2019-11-08
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionAbiraterone Acetate
    PhasePhase 1
    Registry statusCompleted

  • Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer

    NCT04356430 · start 2019-04-01

    Registered record
    Registry ID
    NCT04356430
    Conditions
    Prostate Cancer
    Interventions
    Abiraterone Acetate; Prednisone; Goserelin 10.8 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-04-01
    Completion
    2023-12-01
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbiraterone Acetate; Prednisone; Goserelin 10.8 mg
    PhasePhase 2
    Registry statusUnknown

  • ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

    NCT03903835 · start 2019-02-01

    Registered record
    Registry ID
    NCT03903835
    Conditions
    Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Interventions
    Enzalutamide Oral Capsule; Abiraterone Oral Tablet; Carboplatin; Cabazitaxel 60 mg Solution for Injection; Docetaxel Injectable Solution; Radium Chloride Ra-223; Niraparib plus Abiraterone acetate plus Prednisone; Capivasertib plus Docetaxel; Apalutamide; Darolutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2019-02-01
    Completion
    2026-12
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    InterventionEnzalutamide Oral Capsule; Abiraterone Oral Tablet; Carboplatin; Cabazitaxel 60 mg Solution for Injection +6 more
    PhasePhase 3
    Registry statusRecruiting

  • A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer

    NCT03587285 · start 2018-09-23

    Registered record
    Registry ID
    NCT03587285
    Conditions
    Prostatic Neoplasms
    Interventions
    Tcm+ Goserelin acetate+ Bicalutamide; Tcm+Goserelin acetate+Abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2018-09-23
    Completion
    2021-07-31
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionTcm+ Goserelin acetate+ Bicalutamide; Tcm+Goserelin acetate+Abiraterone acetate
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

    NCT03565835 · start 2018-06-13

    Registered record
    Registry ID
    NCT03565835
    Conditions
    Prostatic Neoplasms
    Interventions
    Abiraterone Acetate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-13
    Completion
    2021-11-17
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionAbiraterone Acetate; Prednisone
    PhasePhase 2
    Registry statusCompleted

  • A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    NCT03431350 · start 2018-03-02

    Registered record
    Registry ID
    NCT03431350
    Conditions
    Prostatic Neoplasms, Castration-Resistant
    Interventions
    Niraparib 200 mg; Cetrelimab 240 mg; Cetrelimab 480 mg; Abiraterone acetate 1000 mg; Prednisone 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-03-02
    Completion
    2026-12-31
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms, Castration-Resistant
    InterventionNiraparib 200 mg; Cetrelimab 240 mg; Cetrelimab 480 mg; Abiraterone acetate 1000 mg +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

    NCT03098836 · start 2017-07-10

    Registered record
    Registry ID
    NCT03098836
    Conditions
    Prostate Cancer
    Interventions
    ARN-509; Abiraterone Acetate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-10
    Completion
    2024-07-09
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionARN-509; Abiraterone Acetate; Prednisone
    PhasePhase 2
    Registry statusCompleted

  • Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

    NCT03012321 · start 2017-01-12

    Registered record
    Registry ID
    NCT03012321
    Conditions
    Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer
    Interventions
    Olaparib; Abiraterone Acetate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-01-12
    Completion
    2027-01-16
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer
    InterventionOlaparib; Abiraterone Acetate; Prednisone
    PhasePhase 2
    Registry statusActive not recruiting

  • Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

    NCT03002220 · start 2016-12-21

    Registered record
    Registry ID
    NCT03002220
    Conditions
    Prostate Cancer
    Interventions
    radium-223
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-21
    Completion
    2021-06-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionradium-223
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

    NCT06473259 · start 2016-12-16

    Registered record
    Registry ID
    NCT06473259
    Conditions
    Prostate Cancer; Hormone Sensitive Prostate Cancer; Metastatic Tumor
    Interventions
    Docetaxel; Apalutamide Oral Tablet; Enzalutamide Oral Tablet; Abiraterone acetate tablets; Darolutamide Oral Tablet; radiotherapy; Triptorelin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2016-12-16
    Completion
    2028-12
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Hormone Sensitive Prostate Cancer; Metastatic Tumor
    InterventionDocetaxel; Apalutamide Oral Tablet; Enzalutamide Oral Tablet; Abiraterone acetate tablets +3 more
    PhaseNot recorded
    Registry statusRecruiting

  • Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

    NCT02861573 · start 2016-11-17

    Registered record
    Registry ID
    NCT02861573
    Conditions
    Metastatic Castration-Resistant Prostate Cancer
    Interventions
    Pembrolizumab 200 mg; Olaparib 400 mg; Docetaxel 75 mg/m^2; Prednisone 5 mg; Enzalutamide 160 mg; Dexamethasone 8 mg; Olaparib 300 mg; Abiraterone acetate 1000 mg; Lenvatinib; Pembrolizumab/Vibostolimab coformulation; Carboplatin; Etoposide; Belzutifan 120mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2016-11-17
    Completion
    2028-07-24
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostate Cancer
    InterventionPembrolizumab 200 mg; Olaparib 400 mg; Docetaxel 75 mg/m^2; Prednisone 5 mg +9 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting